JP Morgan Chase’s Intersect ENT, Inc XENT Stock Holding History

JP Morgan Chase’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-23,300	Closed	-$487K	–	6769
2021 Q1	$487K	Buy	+23,300	New	+$538K	﹤0.01%	4693
2016 Q2	–	Sell	-50,000	Closed	-$950K	–	5052
2016 Q1	$950K	Buy	+50,000	New	+$906K	﹤0.01%	3098

JP Morgan Chase's XENT Position: Q2 2022 in Review

JP Morgan Chase sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 292,931 shares — an estimated $8.2M sold.

JP Morgan Chase first reported a position in XENT in Q3 2014 and held it in 31 quarters. The position peaked at $9.48M in Q3 2021. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

JP Morgan Chase reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
JP Morgan Chase sold 292,931 Intersect ENT, Inc shares in Q2 2022, an estimated $8.2M.
JP Morgan Chase first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 31 quarters.
JP Morgan Chase's Intersect ENT, Inc position peaked at $9.48M in Q3 2021.
0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.